Biogen Inc. (BIIB) Covered Calls
Biogen Inc. is a global biotechnology leader focused on discovering, developing, and delivering innovative therapies for people living with serious neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has pioneered breakthroughs in multiple sclerosis (MS) and spinal muscular atrophy (SMA), and is currently at the forefront of research into Alzheimer’s disease and other complex brain disorders.
You can sell covered calls on Biogen Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for BIIB (prices last updated Thu 1:20 PM ET):
| Biogen Inc. (BIIB) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 176.88 | -6.90 | 176.72 | 177.01 | 563K | 21 | 27 |
| Covered Calls For Biogen Inc. (BIIB) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Apr 17 | 177.5 | 4.30 | 172.71 | 2.5% | 57.0% | |
| May 15 | 175 | 10.00 | 167.01 | 4.8% | 39.8% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Core Business and Products
Biogen’s business model is built on deep expertise in human biology to address high-unmet needs in neurology and immunology. Its portfolio includes market-leading treatments for multiple sclerosis, such as Tecfidera and Tysabri, and the life-altering therapy Spinraza for spinal muscular atrophy. The company is actively expanding its pipeline into Alzheimer’s disease, with a focus on monoclonal antibodies and antisense oligonucleotide (ASO) platforms designed to target the underlying pathology of neurodegeneration.
Competitive Landscape
Biogen competes with both large-cap pharmaceutical giants and specialized biotech firms within the highly challenging neurology sector. Its primary optionable competitors include:
- Amgen (AMGN): A massive biotechnology peer that competes with Biogen across various therapeutic areas and maintains a robust R&D pipeline that challenges Biogen’s market share in complex diseases.
- Regeneron Pharmaceuticals (REGN): A formidable competitor known for high-margin, blockbuster-driven growth; it competes with Biogen by leveraging strong R&D capabilities in immunology and other neurology-related pathways.
- Gilead Sciences (GILD): While historically focused on virology, Gilead’s expansion into broader medical therapies makes it an increasingly relevant competitor for market-share in the long-term therapeutics landscape.
Strategic Outlook and Innovation
Biogen’s strategy is heavily reliant on its "pipeline-first" approach as it pivots away from legacy MS-franchise reliance. By balancing high-risk, high-reward R&D investments in areas like Alzheimer’s and neuro-immunology, the company aims to secure the next generation of neurological breakthroughs. As a highly liquid, optionable stock, Biogen remains a focal point for institutional investors and traders balancing long-term biotech growth prospects against the inherent regulatory and clinical-trial volatility of the industry.
| Top 10 Open Interest For Apr 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | SLV covered calls | 6. | SPY covered calls | 1. | REPL covered calls | |
| 2. | EEM covered calls | 7. | TLT covered calls | 2. | CMPX covered calls | |
| 3. | NVDA covered calls | 8. | HYG covered calls | 3. | AVTX covered calls | |
| 4. | KWEB covered calls | 9. | EWZ covered calls | 4. | APLD covered calls | |
| 5. | QQQ covered calls | 10. | SOFI covered calls | 5. | USAR covered calls | |
Want more examples? BIDU Covered Calls | BIL Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
